Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Quark, Regulus, Alnylam, and More


Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure, and Other Diseases

Patent Number: 8,765,699

Filed: Sept. 27, 2005

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-coding RNAs

Patent Number: 8,765,701

Filed: Dec. 30, 2008

Lead Inventor: Frank Bennett, Regulus Therapeutics

Title: Modified Small Interfering RNA Molecules and Methods of Use

Patent Number: 8,765,704

Filed: Dec. 14, 2011

Lead Inventor: Jang Han, Novartis

Title: Oligonucleotides Inhibiting Cellular Migration

Patent Number: 8,765,705

Filed: July 30, 2010

Lead Inventor: Florence Cabon, National Center for Scientific Research

Title: microRNA-104-5p as a Tumor Suppressor and Sensitizing Agent for Chemotherapy

Patent Number: 8,765,707

Filed: April 23, 2012

Lead Inventor: Preethi Gunaratne, Baylor College of Medicine

Title: Methods and Composition involving miRNA and miRNA Inhibitor Molecules

Patent Number: 8,765,709

Filed: Aug. 28, 2013

Lead Inventor: David Brown, Asuragen

Title: RNA Interference-mediating Small RNA Molecules

Patent Number: 8,765,930

Filed: June 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute (Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts)

Title: Double-stranded Oligonucleotide Compound for Down-regulating the Expression of CASP2 Gene

Patent Number: 8,765,931

Filed: Oct. 22, 2009

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

Title: Compositions and Methods for Inhibiting Expression of XBP-1 Gene

Patent Number: 8,765,932

Filed: Sept. 14, 2012

Lead Inventor: Kevin Fitzgerald, Alnylam Pharmaceuticals

Title: miRNA Target Prediction

Patent Number: 8,768,630

Filed: Feb. 22, 2011

Lead Inventor: Inhan Lee, University of Michigan